{"id":"v-2v-2-t-lymphocyte-based-immunotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vγ2Vδ2 T cells are innate-like lymphocytes that recognize phosphoantigens and stress-induced ligands on tumor and infected cells. This therapy involves ex vivo expansion and/or in vivo activation of these cells to promote cytotoxic killing of malignant cells and enhance overall anti-tumor immunity. The approach leverages the unique ability of gamma-delta T cells to bridge innate and adaptive immunity without requiring MHC presentation.","oneSentence":"Vγ2Vδ2 T lymphocyte-based immunotherapy activates and expands a specialized subset of gamma-delta T cells to enhance anti-tumor immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:38:22.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (specific indications not fully characterized in public literature)"}]},"trialDetails":[{"nctId":"NCT05493267","phase":"PHASE4","title":"A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2022-08-03","conditions":"MDR-TB, Immunotherapy","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Drug combination (zoledronic acid/interleukin 2)"],"phase":"marketed","status":"active","brandName":"Vγ2Vδ2 T lymphocyte-based immunotherapy","genericName":"Vγ2Vδ2 T lymphocyte-based immunotherapy","companyName":"Shanghai Pulmonary Hospital, Shanghai, China","companyId":"shanghai-pulmonary-hospital-shanghai-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vγ2Vδ2 T lymphocyte-based immunotherapy activates and expands a specialized subset of gamma-delta T cells to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (specific indications not fully characterized in public literature).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}